ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.979,50
0,00%
S&P 500
5.955,25
-0,47%
US Dollar vs BRL
5,7662
0,42%
Bitcoin
88.362,26
-0,30%
Brent Oil
72,36
-0,32%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) Notícias

RDHL

Redhill Biopharma (RDHL)

Redhill Biopharma Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RDHL
DataHoraFonteTítuloCódigoCompanhia
25/02/202509:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
25/02/202509:00PR Newswire (US)RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesNASDAQ:RDHLRedhill Biopharma Ltd
04/02/202509:00PR Newswire (US)RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerNASDAQ:RDHLRedhill Biopharma Ltd
03/02/202518:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RDHLRedhill Biopharma Ltd
21/01/202509:00PR Newswire (US)RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedNASDAQ:RDHLRedhill Biopharma Ltd
10/12/202409:00PR Newswire (US)Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentNASDAQ:RDHLRedhill Biopharma Ltd
02/12/202409:00PR Newswire (US)RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtNASDAQ:RDHLRedhill Biopharma Ltd
14/11/202414:22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RDHLRedhill Biopharma Ltd
28/10/202408:00PR Newswire (US)RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDNASDAQ:RDHLRedhill Biopharma Ltd
22/10/202408:00PR Newswire (US)RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryNASDAQ:RDHLRedhill Biopharma Ltd
14/10/202408:00PR Newswire (US)RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentNASDAQ:RDHLRedhill Biopharma Ltd
01/10/202408:00PR Newswire (US)RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansNASDAQ:RDHLRedhill Biopharma Ltd
30/09/202408:00PR Newswire (US)RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041NASDAQ:RDHLRedhill Biopharma Ltd
09/09/202408:00PR Newswire (US)RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesNASDAQ:RDHLRedhill Biopharma Ltd
05/09/202408:00PR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
03/09/202408:00PR Newswire (US)New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 MortalityNASDAQ:RDHLRedhill Biopharma Ltd
29/08/202408:00PR Newswire (US)RedHill Biopharma Announces First Half 2024 Business HighlightsNASDAQ:RDHLRedhill Biopharma Ltd
26/08/202408:00PR Newswire (US)RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, NeuroblastomaNASDAQ:RDHLRedhill Biopharma Ltd
21/08/202408:00PR Newswire (US)Talicia® Launched in the United Arab EmiratesNASDAQ:RDHLRedhill Biopharma Ltd
20/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RDHLRedhill Biopharma Ltd
19/08/202408:00PR Newswire (US)RedHill Announces Positive Obesity and Diabetes Results with OpaganibNASDAQ:RDHLRedhill Biopharma Ltd
16/08/202408:00PR Newswire (US)RedHill Biopharma Announces Plan to Implement ADS Ratio ChangeNASDAQ:RDHLRedhill Biopharma Ltd
13/08/202414:37Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RDHLRedhill Biopharma Ltd
09/08/202408:01Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:RDHLRedhill Biopharma Ltd
07/08/202417:43Edgar (US Regulatory)Form SCHEDULE 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:RDHLRedhill Biopharma Ltd
01/08/202408:00PR Newswire (US)Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's DiseaseNASDAQ:RDHLRedhill Biopharma Ltd
22/07/202408:00PR Newswire (US)RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® LienNASDAQ:RDHLRedhill Biopharma Ltd
09/07/202409:00PR Newswire (US)RedHill Biopharma Terminates License Agreement for Aemcolo®NASDAQ:RDHLRedhill Biopharma Ltd
20/06/202408:23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RDHLRedhill Biopharma Ltd
06/05/202408:00PR Newswire (US)RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035NASDAQ:RDHLRedhill Biopharma Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:RDHL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ONCO3
Oncoclinicas Brasil Serv... ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
RCSL4
RECRUSUL PN
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
VIVR3
VIVER ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios